Letter to the editor: efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis

Expert Opin Drug Saf. 2018 Dec;17(12):1151-1152. doi: 10.1080/17446651.2018.1545367. Epub 2018 Dec 10.

Authors

Fubin Feng¹, Fang Yin², Tingting Zhang³, Cun Liu³, Changgang Sun^{1

4}

Affiliations

¹ a Department of Oncology , Weifang Traditional Chinese Hospital , Weifang , China.
² b Department of Pediatrics , Weifang People's Hospital , Weifang , China.
³ c College of Traditional Chinese Medicine , Shandong University of Traditional Chinese Medicine , Jinan , China.
⁴ d Department of Oncology , Affiliated Hospital of Weifang Medical University , Weifang , China.

PMID: 30523727
DOI: 10.1080/17446651.2018.1545367

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms*
Humans
Network Meta-Analysis
Receptor, ErbB-2
Trastuzumab

Substances

Receptor, ErbB-2
Trastuzumab